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A B S T R A C T
Sensitive, accurate and cost-effective diagnostic tests are urgently needed to detect Zika virus (ZIKV)
infection. Nonstructural 1 (NS1) glycoprotein is an excellent diagnostic marker since it is released in a
hexameric conformation from infected cells into the patient's bloodstream early in the course of the
infection. We established a stable rZNS1-His-expression system in HEK293 cells through lentiviral
transduction. A novel optimization approach to enhance rZNS1-His protein secretion in the mammalian
expression system was accomplished through 50 nM rapamycin incubation followed by serum-free
media incubation for 9 days, reaching protein yields of 10 mg/l of culture medium. Purified rZNS1-His
hexamer was recognized by anti-NS1 antibodies in ZIKV patient's serum, and showed the ability to
induce a humoral response in immunized mice. The obtained recombinant protein is a reliable biological
tool that can potentially be applied in the development of diagnostic tests to detect ZIKV in infected
patients during the acute phase.
© 2020 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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Zika virus (ZIKV), originally discovered in the Ziika forest of
Uganda in 1947 [1], is a mosquito-borne flavivirus that has
emerged as a global health threat after the 2015 outbreak in
Brazil, where devastating congenital defects were documented
[2]. Since its isolation until 2007, only sporadic cases were
reported in many parts of Africa and Asia, with mild clinical
manifestations. The first outbreak occurred in Yap island in 2007
[3], followed by a major outbreak in French Polynesia and the
Pacific Islands in 2013 [4]. Thereafter, ZIKV spread throughout the
South Pacific and eventually to the Americas in 2015 [2]. The size
of the outbreak and links to congenital neurodevelopmental
defects prompted the World Health Organization (WHO) to
declare ZIKV as a public health emergency of international
concern on February 2016 [5].
ZIKV is primarily transmitted to humans from bites of infected
Aedes aegypti or Aedes albopictus mosquitoes [6,7], yet there have
also been cases of sexual [8,9] and materno-fetal transmission [10].
Most ZIKV infections are asymptomatic. Among symptomatic
cases which develop 6–11 days after infection [11], mild signs such
as headache, retro-orbital pain, maculopapular rash, fever,* Corresponding author.
E-mail address: dcastillo@iibintech.com.ar (D.S. Castillo).
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ZIKV gained attention for its causal link to microcephaly in
the children of women infected while pregnant, as well as to
Guillain-Barré syndrome (GBS) in adults [13–15]. The former is a
neurodevelopmental disorder associated with mental retardation,
learning disabilities, behavioral abnormalities, muscle weakness
and altered muscle tone; whereas the latter is an autoimmune
disease that causes flaccid paralysis [16].
ZIKV is a member of the Flaviviridae family, which comprises
other major global pathogens such as dengue virus, West Nile virus
and yellow fever virus. Flavivirus encapsulate a positive-sense RNA
genome that encodes a polyprotein that is co- and post-transla-
tionally cleaved into three structural (C, prM and E) and seven
nonstructural (NS1, NS2A/2B, NS3, NS4A/4B and NS5) proteins [17].
Nonstructural protein 1 (NS1) is a highly conserved glycoprotein
among flaviviruses, which shows a molecular weight of 4655 kDa
depending on its glycosylation status. NS1 exists in multiple
oligomeric forms: it is present in infected cells as a dimer and it is
secreted as a hexameric soluble lipoparticle [18–22]. Intracellular
NS1 has been associated with early steps of viral replication,
whereas secreted NS1 has been involved with immune evasion
[19,23–25]. The extracellular NS1 hexamer is highly immunogenic
during flavivirus infection: high levels of this protein circulate in
the bloodstream of infected patients during the acute phase up to
the ninth day after the onset of the symptoms, and anti-NS1 IgM or
IgG antibodies can be detected within 4–7 or 8 days after the initialC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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glycoprotein into a good diagnostic marker, allowing flavivirus
early detection in infected patients [29].
As with many other mosquito-borne flavivirus diseases, ZIKV
epidemics usually occur in low resource populations, where Aedes
mosquitoes thrive under precarious infrastructure. Given that
most of these regions do not have access to expensive equipment
for traditional diagnostic methods such as polymerase chain
reaction (PCR), as well as stable power to operate the system, a
rapid, accurate, sensitive and accessible diagnostic technique is
urgently needed for the early detection of ZIKV infected
patients [29]. Considering the virus limited detection window
period up to 10 days after virus infection [30], and the current lack
of vaccine and effective treatments available, early diagnosis
can save valuable time for patients that are being treated
symptomatically and is critical in preventing ZIKV propagation
and in the control of future outbreaks. In this context,
development of diagnostic methods based on the detection of
NS1 in the blood of infected individuals combined with the
detection of IgM and IgG antibodies in a dual test is preferred for
an accurate diagnosis [29].
Obtaining a functional ZIKV hexameric NS1 protein for
diagnosis is not trivial. Post-translational modifications play a
critical role in preserving biological functions of proteins. In the
case of NS1, the hydrophilic monomer that is released from the
viral polyprotein to the endoplasmic reticulum (ER) lumen
contains 12 cysteines that form 6 discrete disulfide bonds, which
contribute to its stabilization and correct folding [31,32]. In line
with this, mutagenesis reports have shown that the last 3
cysteines are crucial for NS1 maturation, oligomerization and
secretion [33]. Following cleavage in the ER, the NS1 monomer is
glycosylated by the addition of high-mannose carbohydrate
moieties [20,34]. Next, it rapidly forms dimeric species, leading
to the acquisition of a partially hydrophobic nature and thus
associating with the ER membrane [35]. NS1 traffics from the ER
through the Golgi, where dimeric subunits associate to form
soluble hexamers and exposed carbohydrates are trimmed and
processed to more complex sugars [36,37]. Considering that
bacterial expression systems produce recombinant proteins that
are usually not soluble and lose their structural and immunologi-
cal features of the native viral protein, recombinant protein
production by mammalian cells is preferred since it allows proper
protein folding, post-translational modifications and protein
assembly [38]. With this strategy in mind and considering that
recombinant expression studies have reported that NS1
multimeric species form spontaneously in the absence of other
viral proteins [39,40], the aim of this study consisted of
establishing a stable and optimized recombinant ZIKV NS1
(rZNS1) expression system from HEK293 cells in order to purify
high yields of the hexameric protein, which could potentially be
used in the development of diagnostic tests to detect ZIKV
infection. Stable rZNS1-hexa-histidine (His)-expressing HEK293
cells were generated through transduction with a lentiviral
vector. Enrichment of positive rZNS1-His-expressing cells was
carried out by limiting dilution cloning, obtaining 1E4-C9 clone,
which presented the highest intracellular and secreted rZNS1-His
protein levels. Optimization of rZNS1-His protein secretion in
1E4-C9 HEK293 cells was achieved with 50 nM rapamycin
treatment followed by serum-free media incubation for 9
days, obtaining a 29-fold protein production increase. Purified
rZNS1-His hexamer was recognized by anti-NS1 antibodies in
ZIKV patient's serum and showed the ability to induce a humoral
response in immunized mice. The obtained recombinant protein
may be of significant value for the development of improved
diagnostic methods for the detection of ZIKV in infected patients
during the acute phase.2. Materials and methods
2.1. Cell culture
HEK293 human embryonic kidney cells were grown in
Dulbecco's Modified Eagle Medium (DMEM, Life Technologies)
supplemented with 10 % fetal bovine serum (FBS, Natocor), 50 mg/
ml gentamicin sulfate (Sigma-Aldrich), 2 mM GlutaMAX (Gibco)
and 1 mM sodium pyruvate at 37 C in a 5 % CO2 humidified
atmosphere. When indicated, cells were washed in Phosphate
Buffered Saline (PBS) prior to incubation for the indicated times in
serum-free DMEM at 37 C in 5 % CO2 supplemented as indicated
above.
For hypotonic treatment, cells were incubated in hypotonic
medium (PBS 0.45 % glucose,1 % FBS, 50 mM or 100 mM NaCl) for 1 h.
Rapamycin treatment (50 nM or 100 nM, Sigma) was carried out in
serum-free DMEM for 2 h. Incubation with Earle’s balanced salt
solution (EBSS, GIBCO) was performed for 2 h. Following a washing
step in PBS, the hypotonic medium, rapamycin supplemented media
or EBSS buffer were replaced with serum-free DMEM and cells
were incubated for the indicated times. For DMSO treatment, cells
were washed in PBS and incubated in 0.25 % or 0.50 % DMSO in
serum-free DMEM for the times indicated.
2.2. Lentivirus transduction and cloning
First, lentivirus transfer vector coding for rZNS1 fused to 6xHis
was constructed by subcloning the rZNS1-His fragment from the
pcDNA3.1 (+) vector (Thermo Fisher plasmid V79020) into the
NheI/EcoRI sites of the pLB vector (Addgene plasmid 11619)
(Supplementary Fig. 1).
To produce lentivirus, the transfer vector pLB coding for rZNS1-
His was cotransfected with the packaging vector pSPAX2 (Addgene
plasmid 12260) and the vesicular stomatitis virus (VSV) glycoprotein
vector pMD2.G (Addgene plasmid 12259) into HEK293E cells using
polyethylenimine (PEI, Polysciences) according to the manufac-
turer’s instructions. Supernatant with lentivirus was collected 2 days
after transfection, and low-speed concentration was performed by
overnight centrifugation of the viral supernatant at 3000 g and 4 C.
Concentrated viral supernatants were supplemented with 20 mM 4-
(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) pH 7.4
and 12 mg/ml Polybrene (Sigma). For HEK293 transduction, cells
were infected with lentivirus by centrifugation at 2500 rpm
for 30 min at room temperature (RT). After 4 h of incubation at
37 C in 5 % CO2, inoculum was replaced with complete fresh
medium. rZNS1-His expression was evaluated by flow cytometry (as
described in 2.5. Flow cytometry). Enrichment of HEK293 cells
expressing rZNS1-His was performed cloning twice by limited
dilution, obtaining 1E4-C9 and 1E4-D11 clones with 90 % rZNS1-
His-expressing cells.
2.3. Dot blot
Equal amounts of cell supernatant, 10X supernatant, permeate,
ZIKV stock, mock or rZNS1-His (250 ng) were spotted onto a
Polyvinylidene Difluoride (PVDF) membrane (Hybond-P, GE Health-
care) with a Bio-Dot microfiltration device (Bio-Rad). Immunoblotting
wasperformedasdescribedin2.6.Westernblottingusing 1:1000 ZNS1
mouse polyclonal sera or 1:200 human sera.
2.4. Immunofluorescence
Cells were fixed with 4 % paraformaldehyde for 10 min at RT,
permeabilized with 0.2 % Triton X-100 and incubated with 2 %
bovine serum albumin (BSA) in PBS for 1 h at 37 C. Immuno-
staining was performed using 1:500 ZNS1 mouse polyclonal sera,
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(Invitrogen) and 1.5 mg/ml 40,6-diamidino-2-phenylindole (DAPI)
to visualize nuclei. At least three fields of each stain were
randomly selected for analysis. Image acquisition was performed
with a Nikon Eclipse E600 microscope at a magnification of
1000  . Images were processed with the NIH ImageJ software.
2.5. Flow cytometry
Cells were fixed with 1 % paraformaldehyde for 20 min at 4 C,
permeabilized with cold 90 % methanol in PBS for 30 min at 4 C,
blocked in 2 % BSA in PBS for 1 h at RT and washed in PBS prior to
immunostaining with 4 mg/ml ZNS1 monoclonal antibody (mAbia
labs, Argentina) O.N. at 4 C. Following a washing step in PBS, cells
were incubated for 1 h at RT with Alexa Fluor 488 goat anti-mouse
IgG secondary antibody (Invitrogen) at a 1:100 dilution. Samples
were measured with a CyFlow Space cytometer (Partec). Data
analysis was performed with WinMDI 2.9 software.
2.6. Western blotting
Cell lysates, cell supernatants, purification fractions, rZNS1-His and
gel filtration fractions were resolved on 7 % or 10 % sodium dodecyl
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE). After trans-
fer to a nitrocellulose membrane (Hybond-ECL, GE Healthcare),
analysis by immunoblotting was performed using 0.2 mg/ml ZNS1
monoclonal antibody (mAbia labs, Argentina),1:1000 glyceraldehyde
3-phosphate dehydrogenase (GAPDH, Sigma-Aldrich) or 0.1 mg/ml
anti-His tag monoclonal antibody (mAbia labs, Argentina). Bound
mAbs were recognized with a horseradish peroxidase (HRP) goat anti-
mouse IgG secondary antibody (Sigma-Aldrich) at a 1:2000 dilution,
Alexa Fluor 680 goat anti-mouse IgG secondary antibody (Invitrogen)
at a 1:20000 dilution, or with HRP rabbit anti-human IgG secondary
antibody (Dako) at a 1:10000 dilution. The signal was visualized
with enhanced chemiluminiscence reagent (GE Healthcare) and
CL-XPosure Films (Thermo Scientific), or with an Odyssey Infrared
Imager (Li-Cor). Densitometric analysis was performed using the NIH
ImageJ software.
2.7. MTT assay
HEK293 rZNS1-His 1E4-C9 cells pretreated or not with
rapamycin (as described in 2.1. Cell culture) were incubated in
serum-free media for the indicated times. Cell activity was
assessed by 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium
bromide (MTT, Sigma-Aldrich) assay as described previously [41].
2.8. Cell supernatant concentration
Cell supernatants were concentrated 10 times by ultrafiltra-
tion using a Stirred Ultrafiltration Cell device (Millipore) with a
100 kDa MWCO disc membrane (Millipore).
2.9. Purification
To purify secreted rZNS1-His, supernatant of HEK293 rZNS1-His
1E4-C9 cells treated with 50 nM rapamycin and incubated 9 days in
serum-free media were clarified by centrifugation for 5 min at
1500 rpm and subjected to concentration by ultrafiltration as
described above. The 10-fold concentrated supernatant was
dialyzed in 100 mM NaCl - PBS and loaded on a nickel affinity
column (Pharmacia Biotech) O.N. at 4 C. The column was washed
with 50 mM TrisHCl pH 7.6, 100 mM NaCl, 20 mM imidazole, and
rZNS1-His was eluted with 50 mM TrisHCl pH 7.6, 500 mM NaCl,
and 200 mM imidazole. The purification process was confirmed by
SDS-PAGE and rZNS1-His fractions were dialyzed against PBS.2.10. Gel filtration analysis
For gel filtration analysis, rZNS1-His was dialized in 0.01 M
phosphate buffer, 0.14 M NaCl, pH 7.4 and used as input for a
Superdex 200 Increase 100/300 G L column (GE Healthcare), using
the same buffer. Markers used for molecular weight determination
were Apoferritin (443 kDa), β-amylase (200 kDa) and Bovine
Serum Albumin (66 kDa), all from Sigma. Eluted fractions were
resolved by 10 % SDS-PAGE and analyzed by immunoblot (see 2.6.
Western blotting).
2.11. Cross-linking assay
Dialized rZNS1-His (20 mg) was cross-linked with different
concentrations of glutaraldehyde (Sigma) for 15 min at 37 C.
Subsequently, the protein samples were mixed with Laemmli
buffer, boiled for 5 min, resolved on 7 % SDS-PAGE and analyzed by
immunoblot (as described in 2.6. Western blotting).
2.12. Indirect enzyme-linked immunosorbent assay
Microtiter plates (Nunc Maxisorp 96-well ELISA plates) were
coated with 100 ml of rZNS1-His (400 ng/well) in coating buffer
(0.1 M Na2HPO4 buffer pH 9.5) for 18 h at 4 C. Following incubation
in blocking buffer (5 % skimmed milk in TBS) for 1 h at 37 C, the
plates were further incubated with human sera at a 1:100 dilution,
or with mouse polyclonal sera at the indicated dilutions, for 1 h at
RT in blocking buffer. Following four washing steps in TBS Tween-
20 0.05 %, plates were further incubated in HRP rabbit anti-human
IgG secondary antibody (Dako) at a 1:4000 dilution, or with HRP
goat anti-mouse IgG Fcg fragment specific secondary antibody
(Jackson Immunoresearch) at a 1:2000 dilution, for 1 h at RT in
blocking buffer. Finally, plates were washed four times in TBS
Tween-20 0.05 % and after incubation with the substrate [0.3 %
H2O2, 0.1 % 3,30,5,50-tetramethylbenzidine (TMB) in 0.1 M citric acid
pH 5] for 15–20 min at RT, the reaction was stopped with 0.2 M
H2SO4. The absorbance at 450 nm was measured with a FilterMax
F5 Multi-Mode microplate reader (Molecular Devices).
2.13. Stock virus growth
ZIKV inactivatedstocks wereakindgift fromFedericoGiovannoni
(IQUIBICEN-UBA, CONICET). Briefly, Aedes albopictus C6/36 cells
were grown in 1.5 % FBS Minimum Essential Media (MEM) and
infected with ZIKV PRVABC59 Puerto Rico strain. Supernatants were
collected at different time-points to harvest virus. Virus was
inactivated by UV radiation as described previously [42].
2.14. Immunizations
Mice were obtained from our own breeding facility and
were housed under specific pathogen free (SPF) conditions. 6- to
7-week-old male BALB/c mice were immunized intraperitoneally
with 20 mg of rZNS1-His emulsified in complete Freund's adjuvant.
Booster injections of 10 mg of rZNS1-His in incomplete Freund's
adjuvant were applied 23 and 44 days after the first immunization.
The humoral response of a test bleed performed 7 days after the
final immunization was assessed by indirect-enzyme-linked
immunosorbent assay (iELISA) (see 2.12. Indirect-enzyme-linked
immunosorbent assay). Mice were monitored daily on weekdays.
There were no deaths associated to immunizations or care.
2.15. Statistical analysis
Data analysis was performed with GraphPad Prism 5.0 (Graph-
Pad Software, La Jolla, CA, USA). Statistical differences were
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Bonferroni post hoc analysis for multiple comparisons or with
Dunnett post hoc analysis for multiple comparisons to one control
group. P-values <0.05 were considered significant.
2.16. Ethical statement
The protocol of animal immunization followed in this study was
approved by the Committee on the Ethics of Animal Experiments of
the Universidad Nacional de San Martín, according to the
recommendations of the Guide for the Care and Use of Laboratory
Animals of the National Institutes of Health.
All the sera analyzed in this study came from a previously
characterized serum collection provided by the Hospital de Niños
"Ricardo Gutierrez". ZIKV-positive sera belong to individuals with
positive diagnosis of ZIKV infection. The serum samples had been
codifiedupon collection inorderto ensureanonymityof the patients.
3. Results
3.1. Development and characterization of stable HEK293 cell lines
expressing rZNS1-His
In order to obtain stable rZNS1-His-expressing HEK293 cells,
we first developed the pLB-ZNS1 vector by cloning the rZNS1-His
mammalian codon-optimized fragment encoding a chimeric
protein composed of a Kozak sequence, followed by the signal
peptide of the G protein of VSV, the sequence of MR 766 ZIKVFig. 1. Development of stable rZNS1-His-expressing HEK293 cells. (A) Immunostaining 
HEK293 cells with ZNS1 mouse polyclonal sera. Scale bar, 25 mm. (B) Determination of t
UTD, parental, 1E4, 1E4-C9 and 1E4-D11 rZNS1-His HEK293 cells. Only secondary Ab was
of UTD, 1E4, 1E4-C9 and 1E4-D11 rZNS1-His HEK293 cells with anti-ZNS1 monoclonal a
controls. The position of the molecular mass standards is indicated on the right. Arrowh
mean  SEM of at least three independent experiments. P-values were calculated by oisolate comprising amino acids 791–1142 that correspond to the
NS1 polyprotein, and the C-terminal 6xHis tag into the lentiviral
transfer vector pLB (Supplementary Fig. 1). Lentivirus were
generated by cotransfecting the resulting pLB-NS1 vector with
the packaging vector pSPAX2 and the VSV glycoprotein vector
pMD2.G into HEK293E cells. HEK293 transduction was carried out
by infecting HEK293 cells with the produced lentivirus. rZNS1-His
expression was evaluated by immunostaining (Fig. 1A) and flow
cytometry (Fig. 1B) in the parental transduced cell line, which
showed the stable expression of rZNS1-His protein in 55.2 % of the
cell population (Fig. 1B). With the aim to achieve a higher
percentage of positive rZNS1-His-expressing cells, clonal cell lines
were generated from the parental cells by limiting dilution. 1E4
clone was obtained from the first round of cloning (Fig. 1A),
exhibiting 74.9 % of rZNS1-His positive cells (Fig. 1B). Following a
second round of cloning, two positive clones were selected after
screening (Supplementary Fig. 2): 1E4-C9 and 1E4-D11 (Fig. 1A).
These showed 89.6 % and 88.8 % of positive rZNS1-expressing cells,
respectively (Fig. 1B). Next, to further characterize the rZNS1-His
expression pattern in the clonal cell lines, we performed Western
blot assays to determine the intracellular and secreted rZNS1-His
protein levels. The results revealed that 1E4-C9 cells presented the
highest intracellular (Fig. 1C) and extracellular secreted (Fig. 1D)
expression of rZNS1-His protein. Hence, despite the similar
percentages of positive rZNS1-expressing cells between 1E4-C9
and 1E4-D11 clonal cell lines observed by flow cytometry, we
continued working with 1E4-C9 cells for their significantly higher
intracellular and secreted rZNS1-His protein levels.of untransduced (UTD) HEK293 cells, parental, 1E4, 1E4-C9 and 1E4-D11 rZNS1-His
he percentage of positive rZNS1-His-expressing cells assessed by flow cytometry in
 used as control. (C-D) Western blot analysis of cell extracts (C) and supernatants (D)
ntibody. GAPDH (C) and Coomassie brilliant blue staining (D) were used as loading
eads in (C) indicate rZNS1-His monomer glycosylation pattern. Data represent the
ne-way ANOVA, Bonferroni's: **P < 0.01, ***P < 0.001, n.s. not significant.
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secretion in 1E4-C9 HEK293 cells
Given that we sought to purify rZNS1-His in its hexameric
conformation, which is the conformation of soluble NS1 secreted
into the bloodstream of ZIKV patients during the acute phase of the
disease [29], we studied if rZNS1-His protein secretion could be
enhanced in 1E4-C9 cells. Previous studies have shown that an
increase in protein production in mammalian cells can be achieved
by optimizing the culture medium or by the addition of small
molecule enhancers (SME) to the media [43]. First, we assessed
whether modifications in the culture medium could have an effect
on rZNS1-His secretion in 1E4-C9 cells. Considering that several
reports have described that serum starvation induces protein
expression in human lung A549 epithelial cells [44,45], we tested if
serum depletion was capable of enhancing the recombinant
protein secretion in our stable HEK293 rZNS1-His-expressing cells.
To this purpose, 1E4-C9 cells were incubated in 10 % FBS or serum-
free culture medium without media replacement for 5 or 9 days.
Under serum depletion conditions, we observed an upregulation of
rZNS1-His protein levels in the supernatant of 1E4-C9 cells
following 5 and 9 days of incubation by immunoblot assays
(Fig. 2A). To further obtain quantitative data of the enhancement
effect of serum depletion on 1E4-C9 cells rZNS1-His secretion, we
carried out a Western blot assay of supernatants collected at
different days after serum-free media addition (Fig. 2B). The resultsFig. 2. Optimal conditions for rZNS1-His increased secretion from 1E4-C9 HEK293 cells
from 1E4-C9 cells incubated in the presence or absence of fetal bovine serum (FBS) (A) or
reduction assay in 1E4-C9 cells incubated in serum-free media for the indicated days. (E
1E4-C9 cells subjected to treatment with 50 nM or 100 nM rapamycin (Rapa), 0.25 % or 0.
in serum-free media for 5 or 9 days. (F) MTT assay in 1E4-C9 cells treated or not with 50
brilliant blue staining was used as loading control, filled arrowheads show rZNS1-His 
contained in the serum-free culture media following a PBS washing step, and the pos
represent mean  SEM of at least three independent experiments. P-values were calcu
**P < 0.01, ***P < 0.001, n.s. not significant.showed that significantly higher rZNS1-His accumulation in the
culture media started at day 5, with a maximum at day 9 (Fig. 2C).
The time-course analysis of rZNS1-His secretion was performed
until day 9 because cell viability was reduced to 38 % at that time
point, as assessed by MTT reduction assay (Fig. 2D). The reduced
cell viability was expected since serum starvation is considered an
'environmental stress' that is responsible for inducing cell death
[46,47]. Next, we studied whether addition of SME could further
induce rZNS1-His secretion to the supernatant in serum-starved
1E4-C9 cells. To assess this, we tested the effect of two reported
SME that enhance protein production in cultured mammalian
cells: rapamycin and dimethylsulfoxide (DMSO) [48–50]. In
addition, we analyzed if chromatin relaxation through hypotonic
medium treatment a well-documented chromatin-modifying
agent [51–53], might render the chromatin structure more
accessible to the transcriptional machinery, resulting in increased
transcriptional activity and rZNS1-His protein production in 1E4-
C9 cells. We performed Western blot assays to determine rZNS1-
His protein levels in the supernatant of 1E4-C9 cells harvested 5 or
9 days after rapamycin, DMSO or hypotonic shock treatment
followed by incubation in serum-free culture medium. The results
revealed a significant 2.4-fold and 2.5-fold increase in rZNS1-His
protein secretion in response to the exposure to 50 nM and 100 nM
rapamycin at day 9, respectively (Fig. 2E). Addition of DMSO or
hypotonic medium treatment did not enhance rZNS1-His produc-
tion in serum starved 1E4-C9 cells. In previous work, Balcarcel and. (A-C) Western blot analysis with anti-ZNS1 monoclonal antibody of supernatants
 in serum-free media for the indicated days (B-C). (D) Cell survival assessed by MTT
) Immunoblot analysis with anti-ZNS1 monoclonal antibody of supernatants from
50 % DMSO, or hypotonic medium (50 mM or 100 mM NaCl), followed by incubation
 nM rapamycin and incubated in serum-free media for 9 days. In (A,B,E) Coomassie
position whereas hollow arrowheads show the remaining bovine serum albumin
itions of the molecular mass standards are indicated on the left. Data in (C,D,E,F)
lated by one-way ANOVA, Dunnett's in (C,D) and Bonferroni's in (E,F): *P < 0.05,
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delayed cell death and enhanced monoclonal antibody production
in a hybridoma cell line [49]. To address whether rapamycin could
prevent cell death in response to serum depletion in 1E4-C9 cells,
we measured cell survival by MTT reduction assay 9 days following
50 nM rapamycin treatment and incubation in serum-free media.
We observed that rapamycin treatment did not affect the reduction
in cell viability observed for serum starvation (Fig. 2F). As an
alternative to rapamycin a pharmacological reagent involved in the
regulation of a plethora of cellular pathways such as autophagy
induction, we tested whether EBSS a solution with physiological
pH that also triggers cellular autophagy [54] had the same effect on
rZNS1-His secretion in 1E4-C9 cells. We observed that EBSS led to a
similar increase to rapamycin treatment in rZNS1-His secretion at
day 9 in serum starved 1E4-C9 cells (Supplementary Fig. 3). Taken
together, these results indicate that rZNS1-His protein secretion
can be enhanced through at least 50 nM rapamycin or starvation
treatment followed by serum-free media incubation for 9 days in
1E4-C9 HEK293 cells.Fig. 3. Purification and conformational characterization of secreted rZNS1-His. (A) Nick
of 1E4-C9 cells treated with 50 nM rapamycin and incubated in serum-free media for 9
Western blot analysis with anti-ZNS1 monoclonal antibody of 1E4-C9 supernatant pr
brilliant blue staining was used as loading control. (C) Dot blot analysis with ZNS1 mous
fractions obtained by ultrafiltration with a 100 kDa MWCO disc membrane. (D) Immunob
not to heat (5 min 100 C) and/or 100 mM DTT pretreatment. (E) Gel filtration chrom
quaternary structure (upper panel), and Western blot analysis with anti-His tag monoclo
(F) In vitro cross-linking of rZNS1-His with different concentrations of glutaraldehyde (G
with Coomassie brilliant blue staining (right panel). In (A,B,E) filled arrowheads show 
serum albumin contained in the serum-free culture media following a PBS washing step
the left.3.3. Purification of hexameric rZNS1-His protein
In order to purify rZNS1-His, supernatant of 1E4-C9 cells
exposed to 50 nM rapamycin and incubated in serum-free media
for 9 days was concentrated 10 times by ultrafiltration using a
100 kDa MWCO disc membrane, dialyzed in 100 mM NaCl - PBS
and purified by nickel affinity chromatography. SDS-PAGE analysis
showed that rZNS1-His eluted as a single 48 kDa band in a
defined peak, with purity >95 % (Fig. 3A). The average yield of
recombinant protein produced in the mammalian expression
system described above was 1 mg of purified rZNS1-His protein
per 100 ml of harvested supernatant. The identity of the purified
rZNS1-His protein was confirmed by immunoblotting (Fig. 3B). In
addition, the analysis showed efficient protein manipulation
throughout processing of the supernatant prior to purification.
To determine whether rZNS1-His purified from 1E4-C9 cells
supernatant presented a hexameric conformation as expected, we
carried out a dot blot assay with the harvested supernatant,
filtrate (10X concentrated supernatant, >100 kDa) and permeateel affinity chromatography purification of rZNS1-His from 10X dialyzed supernatant
 days. Fractions collected were visualized by Coomassie brilliant blue staining. (B)
ocessing steps prior to purification by nickel affinity chromatography. Coomassie
e polyclonal sera of 1E4-C9 supernatant, and 10  1E4-C9 supernatant or permeate
lot analysis with anti-ZNS1 monoclonal antibody of purified rZNS1-His subjected or
atography of rZNS1-His showing a molecular mass corresponding to a hexameric
nal antibody of the eluted fractions corresponding to rZNS1-His peak (lower panel).
A) analyzed by Western blot with anti-His tag monoclonal antibody (left panel) and
rZNS1-His position whereas in (B) hollow arrowheads show the remaining bovine
, and in (A,B,D,E,F), the positions of the molecular mass standards are indicated on
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purified rZNS1-His protein. No signal was observed in the
permeate fraction, suggesting that rZNS1-His protein contained
in 1E4-C9 supernatant is a hexamer (Fig. 3C). To further analyze
this notion, a SDS-PAGE with purified rZNS1-His under non-
denaturing conditions was performed. In the absence of heat
denaturation the dimeric conformation was readily detected,
while without heat denaturation and under no reducing condition
it was possible to visualize the hexameric conformation of rZNS1-
His (Fig. 3D). These results are in line with previous reports, which
have shown that NS1 dimer is sensitive to heat denaturation [55],
and that disulfide bonds contribute to NS1 oligomerization [33].
Finally, we confirmed the quaternary structure of rZNS1-His
through gel filtration chromatography, from which we obtained a
single peak with a molecular mass of 292 kDa (Fig. 3E), a size
compatible with a hexameric conformation. Additionally, we
performed a cross-linking assay using different glutaraldehyde
concentrations, which resulted in the formation of a predominant
complex with a molecular mass compatible with a hexameric form
(Fig. 3F). We observed that the absence of heat denaturation
(Fig. 3D) generates a faster-migrating dimer species on SDS-PAGE
than the dimer detected following glutaraldehyde cross-linking of
rZNS1-His (Fig. 3E), which we interpreted as a more compact form
of the protein. Collectively, these results indicate that the purified
rZNS1-His protein from the supernatant of 1E4-C9 cells is a
hexamer as expected.
3.4. rZNS1-His protein is recognized by ZIKV infected patients sera and
induces a humoral response in mice
In order to study the potential use of the produced rZNS1-His
protein to develop diagnostic tests to detect ZIKV infection, we first
characterized the reactivity of anti-NS1 antibodies in ZIKV
patient's serum towards rZNS1-His protein. iELISA assays were
carried out with the sera of two patients with confirmed ZIKV
infection. Data showed that these sera contained IgG antibodies
that recognize the purified rZNS1-His protein (Fig. 4A), suggesting
that this recombinant protein resembles native NS1 protein
conformation and post-translational modifications. Serum from
two healthy individuals did not show reactivity to rZNS1-His as
expected. Next, we compared the reactivity of ZIKV infected
patient's serum against rZNS1-His or the native protein of ZIKV
Puerto Rico strain produced to the supernatant of ZIKV infected
cells in a dot blot assay. The results revealed that ZIKV patient's
serum reacted with rZNS1-His protein as well as with NS1 protein
contained in the supernatant of ZIKV infected cells (Fig. 4B).
Control serum from a healthy donor did not react towards either ofFig. 4. rZNS1-His reactivity with ZIKV infected patients sera and immunogenicity in a mo
a positive diagnosis of ZIKV. Healthy individuals sera were used as negative control. Eac
analysis with the indicated serum samples of rZNS1-His or ZIKV stock obtained from C6/
supernatant was loaded as negative control. (C) iELISA showing humoral responses of m
control. Each point of the curve represents mean  SD of two sample replicates.the NS1 proteins. Finally, we sought to establish whether rZNS1-
His protein could induce a humoral immune response in a mouse
model. To this purpose, mice were immunized intraperitoneally
with the recombinant protein and the presence of anti-NS1
antibodies was determined by iELISA after the second
booster injection. The results demonstrated the immunogenicity
of rZNS1-His protein given that both mice developed an anti-
NS1 humoral response (Fig. 4C). Collectively, these results unveil
the diagnostic potential of the obtained rZNS1-His protein. Our
rZNS1-His protein could potentially be used in the development of
anti-NS1 antibody immunocapture assays, as well as in the
development of NS1 capture ELISAs and lateral flow systems.
4. Discussion
Zika virus received little attention until 2015 outbreak in Brazil,
where a massive epidemic ensued and congenital neurodevelop-
mental defects were associated with maternal ZIKV infection [2].
Given that ZIKV NS1 hexameric glycoprotein is secreted from the
infected cells and released into the patient's bloodstream, typically
before or from the onset of the symptoms [56,57], it results in an
excellent biomarker for early diagnosis. For these reasons, the
present study aimed at establishing a stable and optimized rZNS1
mammalian expression system that would allow the production
and purification of the ZNS1 hexamer. Mammalian expression
systems are the prevailing method chosen for recombinant protein
production among biopharmaceutical companies and academic
laboratories. Mammalian cell hosts provide an attractive alterna-
tive to prokaryotic hosts since they yield properly folded and
assembled proteins, with native-like post-translational modifica-
tions [38,58]. In the present work, we developed a rZNS1-His
expressing mammalian system through lentiviral transduction
followed by dilution cloning of HEK293 cells, which are extensively
used for protein over-expression studies [38]. This approach
allowed the generation of the 1E4-C9 clone.
Enhancement of protein expression can significantly reduce
time and/or cost in the manufacture of many therapeutic proteins.
Several reports have shown that an increase in protein production
in mammalian cells can be achieved by engineering the host cell,
optimizing the culture medium, culturing the cells at low
temperature or by the addition of SME to the media [43,59–63].
With this in mind, we tested whether 1E4-C9 secretion of
hexameric rZNS1-His could be upregulated by culture medium
optimization and SME addition strategies. Serum starvation has
been previously used as a medium optimization strategy for
increased protein expression purposes [44,45]. We established
that the incubation with serum-free media for 9 days yielded theuse model. (A) iELISA of rZNS1-His with serum samples obtained from patients with
h point of the curve represents mean  SEM of three sample replicates. (B) Dot Blot
36 cells infected with ZIKV PRVABC59 Puerto Rico strain. Mock-infected C6/36 cells
ice immunized with rZNS1-His. Non-immunized mouse sera was used as a negative
8 J.S. Roldán et al. / Biotechnology Reports 25 (2020) e00434maximum rZNS1-His protein levels. Next, we studied the potential
enhancement impact of SME addition to the serum-free media on
the already increased rZNS1-His protein levels. The enhancing
compound DMSO or hypotonic medium treatment did not affect
rZNS1-His secretion. DMSO is an antioxidant that has been
reported to increase IL-1β protein production and secretion
through transcriptional upregulation [64]. On the other hand,
hypotonic medium treatment has been shown to enhance protein
expression in a similar mechanism by increasing transcriptional
machinery accessibility to the chromatin [51]. Therefore, our
results suggest that rZNS1-His production and secretion in 1E4-C9
cells is not affected by a transcriptional pathway boost. Neverthe-
less, we determined that 50 nM and 100 nM rapamycin treatment
followed by incubation for 9 days in serum-free culture medium
was able to significantly increase rZNS1-His protein secretion in
our mammalian expression system. We presume that this effect
occurred in response to rapamycin's ability to reduce the overall
cellular biosynthetic burden [65–68], which apparently did not
affect our recombinant protein expression. On the other hand,
rapamycin is involved in the regulation of a plethora of cellular
functions, such as promoting or inhibiting cellular apoptosis [69].
In a previous study, it was reported that rapamycin treatment
significantly delayed cell death and enhanced monoclonal
antibody production in the CRL 1606 hybridoma cell line [49].
We observed that rapamycin treatment did not prevent serum
starvation associated cell death, in line with the notion that the
effects of SME rely on the working conditions and the cell lines
utilized [43]. Furthermore, rapamycin is a well documented
autophagy inducer. Autophagy is a common innate host defense
response after viral infection, although it has been reported that
this catabolic process can also be utilized by some flavivirus to
enhance their replication [70]. In line with this, several studies
have indicated that ZIKV induces autophagy by triggering ER stress
induction [71–74]. Consistent with these findings, in the current
study, rapamycin treatment and subsequent nutrient deprivation
through serum-free media incubation, promoted rZNS1-His
secretion in 1E4-C9 HEK293 cells. Similar results were obtained
by Dupont et. al., who described that IL-1β secretion was
upregulated in response to serum deprivation and rapamycin
treatment, through an unconventional autophagy-based secretory
pathway [75]. As an alternative to rapamycin treatment, we
determined that serum starvation following incubation with EBSS
a saline solution with physiological pH that is usually used to
induce autophagy through starvation pressure, also increased
rZNS1-His secretion in 1E4-C9 HEK293 cells. Further experiments
should be performed to unravel if rZNS1-His increased secretion
following rapamycin and serum-free media incubation is caused
by an enhancement of the autophagic flux.
In summary, a stable and optimized rZNS1-His mammalian
expression system was developed and characterized. Previous
studies have established stable mammalian cell lines that secrete
hexameric rZNS1 [76,77]. Viranaicken et al. developed stable
rZNS1 Vero cells [77], while Liu et al. established stably transduced
HEK293 rZNS1- expressing cells [76]. As Liu's group, we decided to
develop a mammalian expression system utilizing HEK293 cell line
because it has the advantage of suspension-growing, allowing
large-scale culture and protein production. Nevertheless, these
studies did not focus on improving the low yield of purified
recombinant protein obtained from these expression systems, but
rather developed them for research purposes. This is the first work
that describes that rapamycin treatment and serum deprivation
can upregulate up to 29-fold recombinant ZIKV NS1 protein
production in HEK293 cells, reaching protein yields of 10 mg/l of
culture medium. These conditions may be useful in enhancing
research NS1 protein production efficiency and might be consid-
ered for large-scale manufacturing of NS1 recombinant protein.The obtained recombinant ZNS1 hexamer is a reliable biological
tool of great value for ZIKV clinical diagnosis and surveillance
purposes.
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